CM512 for chronic rhinosinusitis with nasal polyps compared with placebo
Tests CM512 against placebo in adults with chronic rhinosinusitis with nasal polyps.
Key facts
- Who runs it
- Beijing Keymed Biosciences Co., Ltd.
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- A Study of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyposis (NEZHA-3)
- Status
- Not yet recruiting
- Phase
- Phase 3
- People taking part
- 240 people, planned
- Started
- Oct 2026
- Expected to end
- Jul 2028
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- CM512
- Placebo
- Record updated
- 8 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with chronic rhinosinusitis with nasal polyps (long-lasting sinus swelling with growths in the nose) and a blocked nose.
- Age
- 18 Years to 75 Years
- Sex
- All sexes can join.
- Disease stage
- Nasal Polyp Score (NPS) of 5 or more, with at least 2 in each side of the nose. Nasal Congestion Score of 2 or 3 at screening, and at least 2 at the start of the study.
- Earlier treatment
- Enough time must have passed since earlier treatments: at least 10 weeks or 5 half-lives (whichever is longer) for IL-4 receptor alpha subunit blockers, 8 weeks or 5 half-lives for whole-body immune-suppressing drugs, and 6 months since sinus surgery, including polyp removal.
Main reasons for not taking part
- Too little time since earlier IL-4 receptor alpha subunit blockers or whole-body immune-suppressing drugs
- Sinus surgery, including polyp removal, less than 6 months ago
- A cancerous or non-cancerous tumor of the nasal cavity
- Not using birth control
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- with chronic rhinosinusitis with nasal polyposis (CRSwNP)
- Nasal Polyp Score (NPS) of ≥5 with a minimum score of 2 in each nasal cavity
- Nasal Congestion Score of 2 or 3 at screening period, and at least 2 at baseline
- Contraception
Who cannot take part
- Not enough washing out period for previous therapy, e.g., less than 10 weeks or 5 half-lives (whichever is longer) for Interleukin (IL)-4 receptor alpha subunit antagonists, less than 8 weeks or 5 half-lives for systemic immunosuppressant, less than 6 months for sinus surgery (including polypectomy).With malignant or benign tumor of nasal cavity
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a multi-center, randomized, double blind, placebo-controlled Phase III study to evaluate the efficacy and safety of CM512, and to observe the life quality of subjects, the Pharmacokinetics, Pharmacodynamics and immunogenicity of CM512 in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP)
The 2 groups in the trial
- CM512 groupTreatment being tested
Treatment: CM512
- Placebo groupPlacebo, for comparison
Treatment: Placebo
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase III Clinical Study to Evaluate the Efficacy and Safety of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyps
- Plain-language title
- CM512 for chronic rhinosinusitis with nasal polyps compared with placeboGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Fit questions
- Built from NCT07807826, who can take part
- Record updated
- 8 September 2026